Bain Capital Life Sciences Investors, LLC 3
3 · Kailera Therapeutics, Inc. · Filed Apr 16, 2026
Insider Transaction Report
Form 3
Holdings
- (indirect: See footnotes)
Series A-1 Preferred Stock
[F1][F3][F4]Exercise: $0.00→ Common Stock (16,875,000 underlying) - (indirect: See footnotes)
Series B Preferred Stock
[F2][F3][F4]Exercise: $0.00→ Common Stock (4,145,768 underlying)
Footnotes (4)
- [F1]Each share of the Issuer's Series A-1 Preferred Stock is convertible, at the option of the holder, into shares of the Issuer's Common Stock on a 1:1 basis and will automatically convert upon the closing of the Issuer's initial public offering. These securities have no expiration date.
- [F2]Each share of the Issuer's Series B Preferred Stock is convertible, at the option of the holder, into shares of the Issuer's Common Stock on a 1:1 basis and will automatically convert upon the closing of the Issuer's initial public offering. These securities have no expiration date.
- [F3]Represents shares of the Issuer's Series A-1 Preferred Stock and Series B Preferred Stock held directly by BCLS Fund IV Investments, LP ("BCLS Fund IV Investments").
- [F4]Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences IV General Partner, LLC ("BCLS Fund IV GP"), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. ("BCLS Fund IV"), which is the managing member of BCLS Fund IV Investments GP, LLC ("BCLS Fund IV Investments GP"), which is the general partner of BCLS Fund IV Investments. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Signature
See signatures included in Exhibit 99.1|2026-04-16